Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis. by Kosmidis, Michalis L et al.
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Neurology Faculty Papers Department of Neurology 
7-1-2019 
Trial of canakinumab, an IL-1β receptor antagonist, in patients 
with inclusion body myositis. 
Michalis L Kosmidis 
University of Athens Medical School 
Dimitris Pikazis 
University of Athens Medical School 
Panayotis Vlachoyiannopoulos 
University of Athens Medical School 
Athanasios G Tzioufas 
University of Athens Medical School 
Marinos C. Dalakas 
Thomas Jefferson University; University of Athens Medical School 
Follow this and additional works at: https://jdc.jefferson.edu/neurologyfp 
 Part of the Neurology Commons 
Let us know how access to this document benefits you 
Recommended Citation 
Kosmidis, Michalis L; Pikazis, Dimitris; Vlachoyiannopoulos, Panayotis; Tzioufas, Athanasios G; 
and Dalakas, Marinos C., "Trial of canakinumab, an IL-1β receptor antagonist, in patients with 
inclusion body myositis." (2019). Department of Neurology Faculty Papers. Paper 201. 
https://jdc.jefferson.edu/neurologyfp/201 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Neurology Faculty Papers by an authorized administrator of the Jefferson 
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu. 
ARTICLE OPEN ACCESS CLASS OF EVIDENCE
Trial of canakinumab, an IL-1β receptor
antagonist, in patients with inclusion body
myositis
Michalis L. Kosmidis, MD, Dimitris Pikazis, MD, Panayotis Vlachoyiannopoulos, MD,
Athanasios G. Tzioufas, MD, and Marinos C. Dalakas, MD, FAAN
Neurol Neuroimmunol Neuroinflamm 2019;6:e581. doi:10.1212/NXI.0000000000000581
Correspondence
Dr. Dalakas
mdalakas@med.uoa.gr
Abstract
Objective
To assess whether canakinumab, a monoclonal antibody against IL-1β approved for auto-
inflammatory diseases, is effective as target-specific therapy in patients with sporadic inclusion
body myositis (sIBM).
Methods
Because in sIBM IL-1β colocalizes with amyloid precursor protein and upregulates amyloid
aggregates enhancing degeneration, targeting IL-1β with canakinumab may arrest disease
progression. On this basis, 5 ambulatory patients with sIBM participated in an institutional
review board–approved open-labeled study with 150 mg canakinumab [4 bimonthly, then
monthly subcutaneous injections] for a mean period of 15.8 months. Patients were assessed
bimonthly with a manual dynamometer in 12 proximal and distal muscles and with grip force
(GF) in both hands. Total muscle strength (TMS) was expressed in kilograms. Efficacy was
defined as >15% increased strength after 12 months.
Results
Patient 1 stopped at month 5 because of 23% loss in TMS and 32.35% in GF; patient 2 showed
37.1% increase in TMS and 13% inGF bymonth 9; patient 3 exhibited 26.7% reduction in TMS
and 10% in GF at month 33; patient 4 showed 6.5% reduction in TMS and 1.6% in GF after 15
months, denoting relative stability; and patient 5 showed 30.4% loss in TMS and 20.8% in GF
after 18 months. In patients 2 and 4, in whom 3-year longitudinal data were available, no effect
on disease progression was noted.
Conclusions
In this long-term, open-label study, canakinumab showed small, but not clinically appreciable,
stabilizing benefits in 2 of 5 patients with sIBM over 1 year, was ineffective in 2 others, and
might have worsened one. No patient improved.
Classification of evidence
This study provides Class IV evidence that canakinumab was ineffective for patients with sIBM.
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Sporadic inclusion body myositis (sIBM) is the most com-
mon inflammatory myopathy above age 50 years with early
involvement of quadriceps femoris, long finger flexors, biceps,
foot dorsiflexors, and mild facial weakness.1 IBM is slowly
progressive, over years, with an estimated mean annual de-
cline in strength by 5.4% based on quantitative muscle
strength testing2 or by a 3.87 modified medical research
council score per year.3 The cause is unclear, but both
inflammatory/autoimmune and degenerative changes coexist
and may enhance each other.1 The autoimmune component
is mainly characterized by activated and clonally expanded
CD8+ cytotoxic T cells invading healthy-appearing and major
histocompatibility complex-I–expressing muscle fibers, over-
expression of costimulatory and adhesion molecules, upre-
gulation of chemokines and cytokines, such as interleukin
(IL)-1α, IL-1β, IL-2, tumor necrosis factor alpha and trans-
forming growth factor, and activation of dendritic cells and
B cells.1,4–9 IL-1β, a potent proinflammatory cytokine se-
creted by monocytes and macrophages, seems to be in the
interface between inflammation and degeneration because it
colocalizes with amyloid precursor protein on muscle fibers
and leads to overexpression of amyloid precursor protein with
subsequent accumulation of β-amyloid, upregulation of in-
ducible nitric oxide synthase, production of nitric oxide, and
cell death of human myotubes exposed to IL-1β.1,7–9 On this
basis, we hypothesized that targeting IL-1βmay arrest disease
progression. Toward this goal, we first conducted a pilot study
with anakinra, a nonselective IL1-receptor antagonist that
blocks the biologic activity of IL-1, in 5 patients with sIBM.10
Anakinra, approved for rheumatoid arthritis, was ineffective in
sIBM.10 We have now tested the efficacy of canakinumab, an
IgGκ monoclonal antibody, that offers a target-specific
blockade of IL-1β, as a more promising approach.
Study design and patients
Canakinumab (Ilaris)
Canakinumab binds with high affinity and specificity to hu-
man IL-1β, blocking its interaction with IL-1 receptors. In this
proof-of-principle, open-label study, we treated 5 patients
with sIBM with 150 mg subcutaneous canakinumab every 8
weeks, following the doses and schedules approved for the
other autoinflammatory conditions, for a mean period of 15.8
months (range 5–33 months). In 3 patients (3, 4, and 5), the
schedule was empirically increased to monthly injections
hoping for a better effect.
Patients
All patients were ambulatory at study entry and fulfilled the
typical clinical and histologic criteria of sIBM.1,5 Two of 5
patients had also participated in our previous negative study
with anakinra, and their available quantitative muscle strength
data were used to assess whether canakinumab had any effect
on disease progression. The patients’ clinical characteristics
are shown in the table.
Muscle strength, expressed in kilograms, was measured with
a muscle dynamometer by the same examiner (M.L.K.) every
1 or 2 months assessing (1) the mean values of bilateral grip
force (GF) and (2) total muscle strength (TMS) based on the
sum score in 6 muscle groups bilaterally (12 groups total):
arm abduction, elbow flexion, wrist extension, hip flexion,
knee extension, and ankle dorsiflexion. All biopsies were
performed and read by us (Prof. Dalakas’s laboratory).
Primary research question
Class IV was defined as >15% increased strength after 12
months.
Standard protocol approvals, registrations,
and patient consents
All participants signed informed consent before the diagnostic
muscle biopsy was performed and before entering the study.
The study protocol was approved by the Institutional Review
Board of the Laikon Hospital, Athens University Medical
School. The study was registered at EudraCT (number: 2014-
004602-15).
Data availability
Anonymized data will be shared by request from any qualified
investigator.
Results
Treatment effect
Patient 1
A 54-year-old man had progressive muscle weakness and at-
rophy for the last 12 years initially treated as polymyositis. The
diagnosis of IBM was confirmed with a muscle biopsy per-
formed 2 years before enrollment. Because of rapid pro-
gression, he was treated with intravenous immunoglobulin,
methotrexate, and mycophenolate without improvement.
He received canakinumab for 5 months, from November
2014 to April 2015. A 23% loss in TMS and 32.35% in GF
was noted over a 5-month period (figure). He continued to
worsen with more generalized weakness including facial
muscles and dysphagia. The accelerated worsening, per-
ceived as possibly related to the study drug, prompted early
treatment discontinuation.
Patient 2
A 45-year-old woman had slowly progressive proximal and
distal muscle weakness and typical clinicohistological features
Glossary
GF = grip force; sIBM = sporadic inclusion body myositis; TMS = total muscle strength.
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of sIBM. She had participated in the anakinra study from 2010
to 2011 without benefit but steady progression. She received
canakinumab from March 2016 to November 2016. A 37.1%
increase in TMS and 13% increase in GF were noted over an
8-month treatment (figure). Of interest, when she received
anakinra, she exhibited a 7.4% increase in TMS and a 30%
decrease in GF10 suggesting a more beneficial effect of canaki-
numab in disease progression. Despite thesemild gains however
demonstrable in our measurements, the patient did not ap-
preciate any positive functional changes in her daily activities
and requested not to continue with additional treatments.
Patient 3
An 80-year-old woman had progressive muscle weakness
for the last 29 years with typical clinicohistologic features of
sIBM. She had received mycophenolate and steroids
without benefit. At study entry, she was ambulatory with
aids. She was treated with canakinumab for 33 months,
from September 2015 until June 2018. A 26.7% loss in TMS
and 10% loss in GF were noted during the study period
(figure). She reported progressive weakness with more
difficulty in her daily activities and felt that the drug was
ineffective.
Figure (A and B) Effect of canakinumab in muscle strength measured in each patient as mean bilateral GF (A) and TMS
(B) during the mean study period of 15.8 months (range 5–33 months)
No significant or clinically meaningful changes were noted in improving strength or stabilizing disease progression. GF = grip force; TMS = total muscle
strength.
Table Main clinical characteristic of patients with sIBM participating in the canakinumab study
Age at
symptom
onset
Disease
duration (y) till
study
participation Initial symptoms
Muscle groups involved
during the course of the
disease and study
participation Dysphagia
Muscle
biopsy
findings
Previous
therapies
Patient
1
42 12 Lower extremity
weakness, followed
by upper extremities
Facial and bulbar muscles;
upper and lower extremity
proximal and distal muscles
Yes Typical
for IBM
IVIg,
methotrexate,
and
myocophenolate
Patient
2
36 10 Upper and lower
proximal and distal
muscles
Upper and lower proximal and
distal muscles
No Typical
for IBM
Anakinra
Patient
3
51 29 Upper and lower
proximal and distal
muscles
Upper and lower proximal and
distal muscles
No Typical
for IBM
Mycophenolate
and steroids
Patient
4
54 14 Upper and lower
proximal and distal
muscles
Upper and lower proximal and
distal muscles
No Typical
for IBM
Mycophenolate,
prednisolone,
and anakinra
Patient
5
65 5 Upper and lower
proximal and distal
muscles
Upper and lower proximal and
distal muscles
Yes Typical
for IBM
No previous
treatments
Abbreviations: IBM = inclusion body myositis; IVIg = intravenous immunoglobulin; sIBM = sporadic inclusion body myositis.
Clinical characteristics of patients with sIBM participated in the canakinumab study. Two of five patients developed overt dysphagia during the disease
course. Patients 2 and 4 had also participated in the previous study with anakinra.10
None of the patients was receiving any other immunotherapy during the study period with canakinumab.
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Patient 4
A 68-year-old man had progressive weakness for the last 14
years and typical sIBM. Treatment with mycophenolate and
prednisolone was ineffective. He received canakinumab for
15 months, from April 2014 until July 2015. A 6.5% re-
duction in TMS with 1.6% reduction in GF were noted
during the study period, a sign we interpreted as disease
stability (figure). He also reported functional improvement
in the use of his hands after the first few months, but this
benefit did not persist or captured in follow-up visits. The
patient had participated in the anakinra study, from January
2010 until October 2010, and exhibited a 3.5% reduction in
TMS and 5% reduction in GF.
Patient 5
A 70-year-old man had a 5-year history of progressive weak-
ness and typical clinicohistologic features of sIBM. He re-
ceived canakinumab for 18 months, from May 2015 to
November 2016. Three months after therapy initiation, he
underwent cholecystectomy for cholelithiasis. Following the
operation, he reported worsening of his weakness and pro-
gressive dysphagia. A reduction in his muscle strength, by
30.4% in TMS and 20.8% in GF, was observed during the 18-
month treatment period (figure).
Discussion
Canakinumab was well tolerated but had a variable effect in
the 5 treated patients with sIBM. None of the patients im-
proved. Two patients showed objective signs of disease sta-
bility, which were not however perceived by them as positively
affecting their daily activities; 2 others continued to progress
with the same pace as before therapy, even during a 33-month
extended study period; and still another with accelerated
disease progression might have worsened.
The ineffectiveness of the drug may be due to various reasons:
(1) the patient’s advanced disease at study entry that might
have precluded clinically perceptive changes; (2) IL-1β
blockade may not be meaningful after the disease is already
advanced, although in vitro has a myotoxic effect and
enhances amyloid accumulation; (3) the dose used might be
insufficient to inhibit the inflammatory and neurodegenera-
tive effect of IL-1β; or (4) IL-1β might not be one of the
primary players that drives progression and neuro-
inflammation in sIBM.
Whether canakinumab will have an effect in disease pro-
gression in a subset of patients with sIBM with early disease
remains uncertain. Such a consideration is entertained be-
cause of the relative stability noted in 2 patients; this effect
was, however, minor, and the rationale to conduct a future
control trial in more patients with early disease using such an
expensive drug may not be warranted.
Study funding
No targeted funding reported.
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